Proteome-wide systems genetics identifies UFMylation as a regulator of skeletal muscle function
- University of Melbourne, Australia
- QIMR Berghofer Medical Research Institute, Australia
- University of California, Irvine, United States
- University of Sydney, Australia
- University of California, Los Angeles, United States
Abstract
Improving muscle function has great potential to improve the quality of life. To identify novel regulators of skeletal muscle metabolism and function, we performed a proteomic analysis of gastrocnemius muscle from 73 genetically distinct inbred mouse strains, and integrated the data with previously acquired genomics and >300 molecular/phenotypic traits via quantitative trait loci mapping and correlation network analysis. These data identified thousands of associations between protein abundance and phenotypes and can be accessed online (https://muscle.coffeeprot.com/) to identify regulators of muscle function. We used this resource to prioritize targets for a functional genomic screen in human bioengineered skeletal muscle. This identified several negative regulators of muscle function including UFC1, an E2 ligase for protein UFMylation. We show UFMylation is up-regulated in a mouse model of amyotrophic lateral sclerosis, a disease that involves muscle atrophy. Furthermore, in vivo knockdown of UFMylation increased contraction force, implicating its role as a negative regulator of skeletal muscle function.
Data availability
The proteomics data generated in this study are deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2019) under the identifiers PXD032729, PXD034913 and PXD035170. The code used for downstream analysis of proteomic data can be found at: https://github.com/JeffreyMolendijk/skeletal_muscle.
Article and author information
Author details
Funding
National Health and Medical Research Council (APP1184363)
- Karen Reue
- Marcus M Seldin
- Benjamin L Parker
National Institute of Health (HL147883)
- Aldons J Lusis
National Institute of Health (DK117850)
- Aldons J Lusis
Weary Dunlop Foundation (NA)
- Benjamin L Parker
The ALS Association (21-DDC-574)
- Paul Gregorevic
- Peter J Crouch
National Health and Medical Research Council (APP2009642)
- Benjamin L Parker
National Health and Medical Research Council (APP2013189)
- Richard J Mills
National Health and Medical Research Council (APP1156562)
- Paul Gregorevic
- Benjamin L Parker
National Institute of Health (HL138193)
- Marcus M Seldin
National Institute of Health (DK130640)
- Marcus M Seldin
National Institute of Health (DK097771)
- Marcus M Seldin
National Institute of Health (GM115318)
- Karen Reue
National Institute of Health (AG070959)
- Aldons J Lusis
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: All rAAV6 intramuscular injection mouse experiments were approved by The University of Melbourne Animal Ethics Committee (AEC ID1914940) and conformed to the National Health and Medical Research Council of Australia guidelines regarding the care and use of experimental animals. All studies involving the use of SOD1G37R mice and non-transgenic littermates were approved by a University of Melbourne Animal Experimentation Ethics Committee (approval #2015124) and conformed with guidelines of the Australian National Health and Medical Research Council.
Copyright
© 2022, Molendijk et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,750
- views
-
- 247
- downloads
-
- 11
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Proteome-wide systems genetics identifies UFMylation as a regulator of skeletal muscle function
eLife 11:e82951.
https://doi.org/10.7554/eLife.82951
Further reading
-
- Computational and Systems Biology
- Genetics and Genomics
Root causal gene expression levels – or root causal genes for short – correspond to the initial changes to gene expression that generate patient symptoms as a downstream effect. Identifying root causal genes is critical towards developing treatments that modify disease near its onset, but no existing algorithms attempt to identify root causal genes from data. RNA-sequencing (RNA-seq) data introduces challenges such as measurement error, high dimensionality and non-linearity that compromise accurate estimation of root causal effects even with state-of-the-art approaches. We therefore instead leverage Perturb-seq, or high-throughput perturbations with single-cell RNA-seq readout, to learn the causal order between the genes. We then transfer the causal order to bulk RNA-seq and identify root causal genes specific to a given patient for the first time using a novel statistic. Experiments demonstrate large improvements in performance. Applications to macular degeneration and multiple sclerosis also reveal root causal genes that lie on known pathogenic pathways, delineate patient subgroups and implicate a newly defined omnigenic root causal model.
-
- Computational and Systems Biology
Artificial intelligence (AI) models have been used to study the compositional regularities of proteins in nature, enabling it to assist in protein design to improve the efficiency of protein engineering and reduce manufacturing cost. However, in industrial settings, proteins are often required to work in extreme environments where they are relatively scarce or even non-existent in nature. Since such proteins are almost absent in the training datasets, it is uncertain whether AI model possesses the capability of evolving the protein to adapt extreme conditions. Antibodies are crucial components of affinity chromatography, and they are hoped to remain active at the extreme environments where most proteins cannot tolerate. In this study, we applied an advanced large language model (LLM), the Pro-PRIME model, to improve the alkali resistance of a representative antibody, a VHH antibody capable of binding to growth hormone. Through two rounds of design, we ensured that the selected mutant has enhanced functionality, including higher thermal stability, extreme pH resistance, and stronger affinity, thereby validating the generalized capability of the LLM in meeting specific demands. To the best of our knowledge, this is the first LLM-designed protein product, which is successfully applied in mass production.
